‘One shunt fits all?’: A comparative laboratory study of antibiotic- impregnated shunt catheters with retrospective clinical correlation
This study reveals significant product-specific biochemical and physical variations among commercially available antibiotic-impregnated shunt catheters, with retrospective data linking the Ares® brand to a significantly higher incidence of unexplained abdominal pain compared to Bactiseal®, suggesting that catheter selection may impact clinical outcomes despite the need for further prospective validation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Hydrocephalus is a condition where fluid builds up inside the brain, creating pressure that can damage delicate tissue. To relieve this pressure, surgeons often insert a thin, flexible tube called a shunt. One end sits in the brain's fluid-filled spaces, and the other travels down to the abdomen, where the fluid is safely absorbed. While this procedure is common and often life-saving, it carries a significant risk: the tube can become infected by bacteria that settle on its surface. To fight this, manufacturers began coating these tubes with antibiotics, specifically a combination of clindamycin and rifampicin, which are released slowly to kill bacteria before they can take hold. For years, doctors have assumed that because these tubes look similar and contain the same named drugs, they all work the same way. However, a new investigation suggests that this assumption might be wrong, revealing that tubes from different companies behave very differently inside the body.
A team of researchers at the National Hospital for Neurology and Neurosurgery in London set out to test this idea by comparing three commercially available antibiotic-coated tubes: Bactiseal, Ares, and XABO. They did not just look at the tubes; they subjected them to a rigorous series of tests that mimicked the conditions inside a human body. First, they measured exactly how much antibiotic was actually inside the plastic of each tube. They found that while the manufacturers claimed specific amounts of drugs, the reality was quite different. One brand, XABO, contained drug levels very close to what was promised. Another, Ares, had slightly less. The third, Bactiseal, had significantly less than claimed, especially in the part of the tube that goes into the brain. They also checked the quality of the antibiotic drug itself. Over time, drugs can break down into other chemicals. The researchers found that the XABO tubes contained the most intact, active drug, while the other two brands had already broken down into more useless byproducts before they were even implanted.
Next, the team watched how these tubes released their medicine over time. They placed sections of the tubes in a warm, flowing saltwater solution that simulated the fluid in the body. They found that the tubes did not release their drugs at the same speed or in the same amounts. The XABO tubes released a large burst of rifampicin early on, while the Ares tubes held onto their clindamycin and released it steadily for a longer period. All three tubes were still able to stop bacteria from growing after two months, but the XABO tubes created the largest protective zone around them. The researchers also looked at the physical nature of the tubes. Using powerful microscopes and special probes, they measured how stiff the tubes were and examined their surface texture. The XABO tubes were the stiffest, while the Ares tubes were the most flexible. When they looked at the surface under a microscope after the tubes had been in the saltwater, they saw that the Bactiseal tubes collected the most debris and deposits, whereas the XABO tubes remained relatively clean and smooth.
To see if these laboratory differences mattered to real patients, the researchers looked back at medical records from their own hospital. They reviewed the cases of nearly 400 patients who had received these shunts. They were looking for a specific problem: abdominal pain that could not be explained by infection or a blocked tube. The results were striking. Nearly half of the patients with Ares tubes reported this unexplained abdominal pain, whereas only about one in ten patients with Bactiseal tubes had the same issue. After adjusting for factors like age and the severity of the patient's condition, the data showed that patients with Ares tubes were still far more likely to suffer from this pain than those with Bactiseal tubes. The study did not find a link between the pain and the XABO tubes, simply because that brand was not used in the hospital during the time period they reviewed.
The researchers are careful to state that they have not proven that the chemical or physical differences they found in the lab are the direct cause of the pain. They have not shown that the drug breakdown or the tube stiffness is what makes patients hurt. However, they have established a clear connection: tubes that are labeled as doing the same job are actually chemically and physically different, and patients with one specific type of tube reported pain much more often than those with another. This suggests that when doctors choose a shunt, they cannot assume all antibiotic-coated tubes are interchangeable. The choice of tube might influence not just the risk of infection, but also the comfort of the patient. The study serves as a call for more research to understand exactly why these differences exist and how they affect patients, urging the medical community to look beyond the label and consider the specific properties of the device being implanted.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.